According to the 2026 Obstetric Anaesthetists’ Association (OAA) guidelines on remifentanil patient-controlled analgesia (PCA) for labour analgesia, remifentanil PCA provides effective labour analgesia, with better pain relief than other parenteral opioids or nitrous oxide alone but less effective analgesia than epidural analgesia. The guidelines recommend administration as PCA demand boluses without a continuous background infusion, using a 2-minute lockout and an incremental dosing approach starting at 20–30 mcg per bolus, with reduction to 10–20 mcg or escalation to 30–40 mcg based on analgesia and adverse effects. Continuous oxygen saturation monitoring and uninterrupted one-to-one observation are recommended due to risks of sedation, respiratory depression, desaturation, and apnea; supplemental oxygen should be administered when SpO₂ falls below 94%. Although multiple dosing regimens have been studied, the optimal bolus dose remains uncertain, and further research is needed. [1]
The 2026 National Institute for Health and Care Excellence (NICE) guideline on intrapartum care evaluates intravenous remifentanil PCA as an option for ongoing pain relief during labor and birth. NICE recommends considering 40 mcg per PCA bolus with a 2-minute lockout period, with this dose selected based on the more recent and larger studies and its use in clinical practice. Compared with intramuscular pethidine, remifentanil PCA was associated with fewer requests for epidural analgesia and forceps or ventouse births and more spontaneous vaginal births, but with greater supplemental oxygen requirements and reduced maternal oxygen saturation; maternal respiratory rate <8 breaths/min, cesarean birth, labor pain, and maternal satisfaction were similar between groups. Due to the risk of maternal respiratory depression, remifentanil PCA should only be used in obstetric units with continuous one-to-one care, respiratory observation and pulse oximetry, immediately available supplemental oxygen, established procedures for respiratory depression, and immediate anesthetic support. NICE noted concerns regarding the quality and heterogeneity of the evidence, which limited the strength of its recommendation. [2]
A 2025 narrative review evaluated the efficacy, safety, and dosing of remifentanil PCA for labor analgesia. Remifentanil PCA provided mild-to-moderate pain relief and was less effective than epidural analgesia but more effective than nitrous oxide and other systemic opioids; reported regimens generally used 10–50 mcg boluses with a 2-minute lockout, with or without background infusion. The authors’ institutional protocol uses 20–40 mcg boluses with a 2-minute lockout and no continuous background infusion, starting at the lower end and increasing stepwise based on pain, respiratory parameters, and sedation. Maternal respiratory depression, apnea, and transient oxygen desaturation were identified as safety concerns, and the review emphasized incremental dosing, continuous monitoring, supplemental oxygen, one-to-one supervision, and anesthesia team availability. [3]
A comprehensive review states higher bolus doses of remifentanil may provide better analgesia but more maternal side effects, while lower bolus doses can produce fewer side effects but inadequate analgesia. One study demonstrated that remifentanil intravenous PCA with a bolus dose of 0.25 to 0.5 mcg/kg without a background infusion significantly reduced pain scores from baseline in 90% of the patients with minimal maternal and neonatal adverse effects. [4]
A dose-finding study observed the median effective PCA bolus dose of remifentanil to be 0.4 mcg/kg, but there was a wide individual variation of 0.2 to 0.8 mcg/kg. They reported slight sedation in all patients, oxygen desaturation (defined by a SpO2 <94%) in 59% of women, fetal heart rate changes in 24% of women, and low Apgar scores in 5.8% of neonates. More recently, a stepwise increase in the bolus dose of PCA remifentanil for labor analgesia was investigated, starting from 0.15 mcg/kg without a maximum limit. They found a significant reduction in the mean pain scores in the first 3 hours and high patient satisfaction in 93% of women. They, however, noted a reduction of respiratory rate and oxygen saturation, without any serious complications, in mothers or neonates. [4]
In an attempt to determine the optimum dose of remifentanil IV PCA for labor analgesia, one study compared variable infusion (0.025 to 0.1 mcg/ kg/min with constant bolus of 0.25 mcg/kg), with variable boluses (0.25 to 1 mcg/kg with constant infusion at 0.025 mcg/kg/min). The pain scores, satisfaction scores, and cumulative doses of remifentanil were found to be similar between the two groups but maternal side effects such as drowsiness and desaturation were higher in the variable bolus group than the variable infusion group. As a result, they concluded that the regimen of increasing background infusion with a fixed PCA bolus could be more appropriate than fixed background infusion with an increasing PCA bolus. [4]
Another study assessed the efficacy and safety of continuous remifentanil infusion, with no boluses, in 205 parturients. They found that infusing remifentanil starting at a rate of 0.025 mcg/kg/min with stepwise increments to a maximum of 0.15 mcg/kg/min resulted in significant reductions in pain scores from baseline, with minimal maternal and neonatal side effects. There was no case of oxygen desaturation or any changes in heart rate variability. Additionally, a prospective, double-blinded randomized controlled trial comparing maternal and neonatal effects of remifentanil PCA. A stepwise increase in the bolus from 0.1 to 0.4 mcg/kg was compared to continuous infusion with increases from 0.05 to 0.2 mcg/kg/min. It was revealed that the adverse effects were similar between both groups. Results from this trial suggest that remifentanil PCA provides better pain relief and similar placental transfer, but 6 of the women in the trial chose to cross over to epidural analgesia because their analgesia was unsatisfactory, suggesting that the maximum dose in this trial may have been too low. [4]
Labor analgesia with IV remifentanil has been reported to be associated with excessive maternal sedation and oxygen desaturation, as well as fetal heart decelerations, depending on the dose and administration regimen. There was a case of respiratory arrest with bradycardia reported with remifentanil PCA administered with a PCA bolus of 40 mcg, due to unknown reasons. There was another case of cardiorespiratory arrest in a woman who underwent induction of labor using remifentanil PCA, which consisted of 40 mcg given as a bolus with a maximum dose of 5 mg per 4 hours. She had received 60 mg of oral codeine phosphate and diamorphine 10 mg intramuscularly in addition to Entonox during labor. The patient fully recovered after resuscitation but the exact reason for the arrest remains unclear. Remifentanil readily crosses the placenta and neonates could theoretically experience the same side effects as their mothers but there were no case reports/studies of serious neonatal adverse events. [4]
A meta-analysis compared the efficacy and safety of remifentanil PCA and epidural analgesia for labor pain relief from five randomized, controlled trials. It was determined that remifentanil PCA does not provide better analgesic efficacy than epidural analgesia during labor but could be an optional effective alternative for pain relief. The safety of remifentanil still remains controversial, but it has been reported that maternal sedation and respiratory depression may occur during labor with remifentanil use. Therefore, remifentanil PCA requires monitoring, one-on-one nursing care throughout labor, and supplemental oxygen in some parturients. [5]
A Cochrane review and meta-analysis included 20 randomized controlled trials of women receiving remifentanil PCA compared to other methods of parental pain management during labor. Evidence showed women in the remifentanil PCA group were more satisfied with pain relief than women in the other opioids group (95% confidence interval [CI] 0.72 to 3.49). There is evidence that remifentanil PCA provided stronger pain relief at one hour than other opioids (95% CI -2.96 to -0.48). [6]
There is no evidence that remifentanil PCA was associated with an increased risk for maternal respiratory depression when compared to epidural analgesia (relative risk [RR] 0.91, 95% CI 0.51 to 1.62). Additionally, there is no evidence that remifentanil PCA was associated with an increased risk for newborns with Apgar scores less than seven at five minutes compared to epidural analgesia (RR 1.26, 95% CI 0.62 to 2.57). There is evidence, however, that remifentanil PCA was associated with a lower risk for the requirement of additional analgesia when compared to other opioids (RR 0.57, 95% CI 0.40 to 0.81). [6]
A 2017 meta-analysis including eight randomized controlled trials (N= 2,351 patients) investigated whether remifentanil patient-controlled analgesia (R-PCA) is associated with significant differences in maternal satisfaction, analgesic efficacy, and safety compared to conventional epidural analgesia (EA). The pooled data analysis did not demonstrate a significant difference in the primary outcome of maternal satisfaction between the groups. Hypoxemia incidence was higher in R-PCA compared to EA (odds ratio [OR] 7.48, 95% confidence interval [CI] 3.42 to 16.36). The visual analog pain score at 1 hour was slightly higher with R-PCA versus EA (weighted mean difference [WMD] 1.33, 95% CI 0.30 to 2.36). R-PCA resulted in reduced pruritus incidence versus EA (OR 0.54, 95% CI 0.32 to 0.89). There were insignificant differences in Visual Analog Score for Pain (VAS) at 2 and 3 hours; the need for a cesarean section; respiratory depression; umbilical pH; neonatal Appearance, Pulse, Grimace, Activity, and Respiration score at 1 and 5 minutes; and incidence of nausea and vomiting. Overall, this meta-analysis remains underpowered and is subject to publication biases for several outcomes, including the primary end-points. The results of this meta-analysis should be interpreted with caution, given the heterogeneity among its studies. [7]
Another meta-analysis provides quality evidence that a remifentanil PCA provides better analgesia for labor than intramuscular or intravenous pethidine with almost comparable maternal adverse effects. However, epidural analgesia was found to provide better pain relief than remifentanil. The conclusions of the comparison of remifentanil with inhalational nitrous oxide and fentanyl are less clear due to limited data. As there were few randomized trials included in the meta-analysis, with few adverse effects reported, an appropriate risk-to-benefit analysis is currently not possible. Large randomized controlled trials reporting on safety issues and patient satisfaction using appropriate administration modes are needed to complement the knowledge of this alternative method for pain relief during labor. [8]